Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
暂无分享,去创建一个
Axel Benner | John D. Shaughnessy | Thomas Hielscher | Bart Barlogie | Hartmut Goldschmidt | Dirk Hose | Bernard Klein | Anja Seckinger | Jens Hillengass | Anna Jauch | T. Rème | J. Rossi | B. Klein | J. Moreaux | D. Hose | H. Goldschmidt | A. Jauch | B. Barlogie | J. Shaughnessy | T. Hielscher | A. Benner | A. Seckinger | K. Neben | U. Bertsch | J. Hillengass | Yiming Zhou | Thierry Rème | Jérôme Moreaux | Tobias Messner | Yiming Zhou | Uta Bertsch | Kai Neben | Thomas Möhler | Jean François Rossi | T. Möhler | Tobias Messner
[1] G. Malerba,et al. Supplementary Figure S4 , 2012 .
[2] D. Fanelli,et al. Supplementary Table S3 , 2007 .
[3] G. Malerba,et al. Supplementary Figure S2 , 2012 .
[4] A. Chinnaiyan,et al. Supplementary Figure S3 , 2012 .
[5] T. Rème,et al. Induction of angiogenesis by normal and malignant plasma cells. , 2009, Blood.
[6] Axel Benner,et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. , 2008, Blood.
[7] J. D. Vos,et al. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis , 2009, Oncogene.
[8] Laurence Lodé,et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Rainer Spang,et al. Microarray Based Diagnosis Profits from Better Documentation of Gene Expression Signatures , 2008, PLoS Comput. Biol..
[10] Hartmut Goldschmidt,et al. A new method for class prediction based on signed-rank algorithms applied to Affymetrix® microarray experiments , 2008, BMC Bioinformatics.
[11] Paolo G. V. Martini,et al. PANP - a New Method of Gene Detection on Oligonucleotide Expression Arrays , 2007, 2007 IEEE 7th International Symposium on BioInformatics and BioEngineering.
[12] R. Bataille,et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.
[13] Yongsheng Huang,et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.
[14] John Crowley,et al. The molecular classification of multiple myeloma. , 2006, Blood.
[15] Yongsheng Huang,et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. , 2006, Blood.
[16] John Crowley,et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. , 2006, Blood.
[17] J. D. Vos,et al. Molecular Classification of Multiple Myeloma (MM) Based on Gene Expression Profiling (GEP) and Fluorescence In Situ Hybridisation (FISH) Is an Independent Predictor for Event Free Survival (EFS). , 2005 .
[18] D. Hose,et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics , 2005, Genes, chromosomes & cancer.
[19] P. L. Bergsagel,et al. Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] V. Pantesco,et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. , 2005, Blood.
[21] Bart Barlogie,et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.
[22] P. Renhowe,et al. Inhibitors of kinesin motor proteins--research and clinical progress. , 2005, Current opinion in drug discovery & development.
[23] J. Penninger,et al. The role of endothelial PI3Kgamma activity in neutrophil trafficking. , 2005, Blood.
[24] J. Crowley,et al. International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] F. Magrangeas,et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma , 2005, Leukemia.
[26] T. Rème,et al. A New Molecular Classification of Multiple Myeloma Using Gene Expression Profiling and Fluorescence In Situ Hybridisation as Predictor for Event Free Survival. , 2004 .
[27] F. Magrangeas,et al. Ploidy, as Detected by Fluorescence In Situ Hybridization, Defines Different Subgroups in Multiple Myeloma. , 2004 .
[28] R. Kyle,et al. Drug therapy: Multiple myeloma , 2004 .
[29] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[30] Rafael A. Irizarry,et al. A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .
[31] E. Stathopoulos,et al. Ki-67 Proliferation Index: Correlation With Prognostic Parameters and Outcome in Multiple Myeloma , 2004, American journal of clinical oncology.
[32] A. Murray,et al. Recycling the Cell Cycle Cyclins Revisited , 2004, Cell.
[33] R. Bataille,et al. Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report , 2004 .
[34] P. Bergsagel,et al. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma , 2003, Immunological reviews.
[35] K. Tarte,et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. , 2002, Blood.
[36] T. Therneau,et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. , 2001, Blood.
[37] H. Kaufmann,et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. , 2000, Blood.
[38] J. D. Vos,et al. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors , 2000, Leukemia.
[39] H. Kaufmann,et al. Deletion of 13 q 14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization , 2000 .
[40] Christian A. Rees,et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[41] T. Therneau,et al. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders , 1999, British journal of haematology.
[42] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[43] K. Tarte,et al. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. , 1998, Blood.
[44] R. Lamerz,et al. Plasma cell proliferation in monoclonal gammopathies: measurement using BU-1 antibody in flow cytometry and microscopy: comparison with serum thymidine kinase. , 1995, Journal of clinical pathology.
[45] Marcos González,et al. A New Staging System for Multiple Myeloma Based on the Number of S-Phase Plasma Cells , 1995 .
[46] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[47] J. S. San Miguel,et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. , 1995, Blood.
[48] M. Jourdan,et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. , 1994, Blood.
[49] W. O'Fallon,et al. Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma , 1993 .
[50] Lust,et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. , 1993, Blood.
[51] W. O'Fallon,et al. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. , 1988, Blood.
[52] T. Habermann,et al. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. , 1987, Mayo Clinic proceedings.
[53] B. Bast,et al. Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique , 1986, British journal of haematology.
[54] B. Durie. Staging and kinetics of multiple myeloma. , 1982, Seminars in oncology.
[55] F. Mandelli,et al. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy , 1984, British journal of haematology.
[56] B. Barlogie,et al. Ploidy and proliferative characteristics in monoclonal gammopathies. , 1982, Blood.
[57] B. Barlogie,et al. The growth fraction of human myeloma cells. , 1981, Blood.
[58] S. Salmon,et al. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.
[59] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.